Chiesi widens rare disease portfolio with $1.9bn KalVista buyout

Thursday, April 30, 2026Robert BarrieView original

Chiesi will assume ownership of Ekterly, an on-demand pill approved for hereditary angioedema.

Read the full article on the original site.